Characterization of an mGluR2/3 Negative Allosteric Modulator in Rodent Models of Depression
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
There is growing evidence suggesting that antagonists of group II metabotropic glutamate receptors (mGluR2/3) exhibit antidepressant-like properties in several preclinical models of depression. However, all those studies have been performed using competitive group II non-selective orthosteric antagonists. In this study we extensively characterized a group II selective negative allosteric modulator (4-[3-(2,6-Dimethylpyridin-4-yl)phenyl]-7-methyl-8-trifluoromethyl-1,3-dihydrobenzo[b][1,4]diazepin-2-one, namely RO4491533, Woltering et al., 2010) in several in vitro biochemical assays and in vivo models of depression. In vitro, RO4491533 completely blocked the glutamate-induced Ca(2+) mobilization and the glutamate-induced accumulation in [(35)S]GTP(γS) binding in cells expressing recombinant human or rat mGluR2 and in native tissues. Results from Schild plot experiments and reversibility test at the target on both cellular and membrane-based assays confirmed the negative allosteric modulator properties of the compound. RO4491533 was equipotent on mGluR2 and mGluR3 receptors but not active on any other mGluRs. RO4491533 has acceptable PK properties in mice and rats, is bioavailable following oral gavage (F = 30%) and brain-penetrant (CSF conc/total plasma conc ratio = 0.8%). RO4491533 appeared to engage the central mGluR2 and mGluR3 receptors since the compound reversed the hypolocomotor effect of an mGluR2/3 orthosteric agonist LY379268 in a target-specific manner, as did the group II orthosteric mGluR2/3 antagonist LY341495. RO4491533 and LY341495 dose-dependently reduced immobility time of C57Bl6/J mice in the forced swim test. Also, RO4491533 and LY341495 were active in the tail suspension test in a line of Helpless (H) mice, a putative genetic model of depression. These data suggest that mGluR2/3 receptors are viable targets for development of novel pharmacotherapies for depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetic Epidemiology of Major Depression: Review and Meta-Analysis
Sullivan, P. F., Neale, M. C., & Kendler, K. S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.10.1552 · Cited by 3,431 · cited 1×
“…subtypes of depression have been described, the major depressive disorder (MDD), often referred to as unipolar depression, is considered the predominant form (for review see Sullivan et al., 2000) and therefore has been the primary focus of antidepression drug development efforts for decades.”
BackgroundAllosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders
Jeffrey Conn, P., Christopoulos, A., & Lindsley, C. W. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2760 · Cited by 1,063
Regulation of Neurotransmitter Release by Metabotropic Glutamate Receptors
Cartmell, J., & Schoepp, D. D. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0750889.x · Cited by 883 · cited 1×
“…coupled to adenylate cyclase via activation of G α i protein, is presynaptically localized, and its activation leads to inhibition of glutamate release in the synapse as autoreceptors (Cartmell & Schoepp, 2000), as well as other neurotransmitters as heteroreceptors (Zwienenberg et al., 2001).”
BackgroundGlutamate and Depression: Clinical and Preclinical Studies
PAUL, I. A., & SKOLNICK, P. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.016 · Cited by 408 · cited 1×
“…stroke, neurodegenerative diseases, epilepsy, schizophrenia, attention-defi cit hyperactivity disorder (ADHD), bipolar disorder, obsessive-compulsive disorder, and MDD (Clinton et al., 2003; Danysz et al., 1995; McCullumsmith & Meador-Woodruff, 2002; Paul & Skolnick, 2003; Rosenberg et al., 2000).”
ROSENBERG, D. R., MacMASTER, F. P., KESHAVAN, M. S., FITZGERALD, K. D., STEWART, C. M., & MOORE, G. J. (2000) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200009000-00008 · Cited by 377
Chaki, S., Yoshikawa, R., Hirota, S., Shimazaki, T., Maeda, M., Kawashima, N., Yoshimizu, T., Yasuhara, A., Sakagami, K., Okuyama, S., et al. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2003.10.009 · Cited by 254
Cited by
Sex differences in glutamate receptor gene expression in major depression and suicide
Gray, A. L., Hyde, T. M., Deep-Soboslay, A., Kleinman, J. E., & Sodhi, M. S. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.91 · Cited by 250
Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status
Henter, I. D., Park, L. T., & Zarate, C. A. (2021) · CNS Drugs · doi:10.1007/s40263-021-00816-x · Cited by 142
“Although both orthosteric and allosteric mGlu2/3 receptor modulators have been shown to exert antidepressant effects, the potency of allosteric modulators was found to be weaker than that of orthosteric antagonists [117].”
BackgroundCognitive impairment in major depression and the mGlu2 receptor as a therapeutic target
Goeldner, C., Ballard, T. M., Knoflach, F., Wichmann, J., Gatti, S., & Umbricht, D. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.08.001 · Cited by 96
“Potent mGlu2/3 antagonists which have been evaluated in rodent tests that are indicative of antidepressant activities, include MSG0039 (Chaki et al., 2004), LY341495 (Kingston et al., 1998), as well as RO4491533 (Woltering et al., 2010; Campo et al., 2011).”
BackgroundInfluentialmGlu2/3 Receptor Antagonists as Novel Antidepressants
Chaki, S. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.03.008 · Cited by 73
Dogra, S., & Conn, P. J. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108687 · Cited by 71
Metadata
- Authors
- Campo, B., Kalinichev, M., Lambeng, N., Yacoubi, M. E., Royer-Urios, I., Schneider, M., Legrand, C., Parron, D., Girard, F., Bessif, A., Poli, S., Vaugeois, J.-M., Poul, E. L., & Celanire, S.
- Venue
- Journal of Neurogenetics
- Publisher
- Informa UK Limited
- Published
- 2011-11-17
- Volume
- 25
- Issue
- 4
- Pages
- 152-166
- ISSN
- 0167-7063 (ISSN-L)
- 1563-5260
- OpenAlex
- W1985791632
- Cited by
- 78
- References
- 6
- FWCI
- 4.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Characterization of an mGluR2/3 Negative Allosteric Modulator in Rodent Models of Depression. https://app.cochat.ai/papers/10.3109/01677063.2011.627485
- The paper
- Campo, B., Kalinichev, M., Lambeng, N., Yacoubi, M. E., Royer-Urios, I., Schneider, M., Legrand, C., Parron, D., Girard, F., Bessif, A., Poli, S., Vaugeois, J.-M., Poul, E. L., & Celanire, S. (2011). Characterization of an mGluR2/3 Negative Allosteric Modulator in Rodent Models of Depression. Journal of Neurogenetics. https://doi.org/10.3109/01677063.2011.627485
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.